Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 211

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

Open access
Pal, Sumanta Kumar, Albiges, Laurence, Tomczak, Piotr, Suárez, Cristina, Voss, Martin H, de Velasco, Guillermo, Chahoud, Jad, Mochalova, Anastasia, Procopio, Giuseppe, Mahammedi, Hakim, Zengerling, Friedemann, Kim, Chan, Osawa, Takahiro, Angel, Martín, Gupta, Suyasha, Khan, Omara, Bergthold, Guillaume, Liu, Bo, Kalaitzidou, Melania, Huseni, Mahrukh, Scheffold, Christian, Powles, Thomas, Choueiri, Toni K · 2023 · The Lancet

Abstract

Summery Background Immune checkpoint inhibitors are the standard of care for first-line treatment of metastatic renal cell carcinoma, yet optimized treatment of patients whose disease progresses after these therapies is unknown. The aim of this study was to determine if adding atezolizumab to cabozantinib delayed disease progression and prolonged survival in patients with disease progression on or after prior immune checkpoint inhibitor treatment. Methods In this phase III, randomized, open-label trial, patients with locally advanced or metastatic renal cell carcinoma whose disease progressed with immune checkpoint inhibitors were randomly assigned 1:1 to atezolizumab (1200 mg intravenously every 3 weeks) plus cabozantinib (60 mg orally once daily) or cabozantinib alone. Multiple primary efficacy end points were progression-free survival per blinded independent central review and overall survival. Secondary end points included safety. The trial is registered with ClinicalTrials.gov, NCT04338269, and is closed to further accrual. Findings From July 28, 2020, to December 27, 2021, 522 patients in 15 countries were assigned to receive atezolizumab-cabozantinib (263 patients) or cabozantinib (259 patients). At data cutoff (January 3, 2023), median follow-up was 15·2 months (interquartile range, 10.7 to 19.3). Median progression-free survival was 10·6 months (95% confidence interval [CI], 9·8 to 12·3) with atezolizumab-cabozantinib and 10·8 months (95% CI, 10·0 to 12·5) with cabozantinib (hazard ratio for disease progression or death, 1·03; 95% CI, 0·83 to 1·28; P=0·78). The hazard ratio for death with atezolizumab-cabozantinib compared with cabozantinib was 0·94 (95% CI, 0·70 to 1·27; P=0·69). Serious adverse events occurred in 48·1% of 262 patients in the atezolizumab-cabozantinib group and 32·8% of 256 patients in the cabozantinib group; adverse events leading to death occurred in 6·5% and 3·5%, respectively. Interpretation The addition of atezolizumab to cabozantinib did not improve clinical outcomes and led to increased toxicity. These results should discourage sequential use of immune checkpoint inhibitors in renal cell carcinoma outside of clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(23)00922-4

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 211

Metadata

Authors
Pal, S. K., Albiges, L., Tomczak, P., Suárez, C., Voss, M. H., de Velasco, G., Chahoud, J., Mochalova, A., Procopio, G., Mahammedi, H., Zengerling, F., Kim, C., Osawa, T., Angel, M., Gupta, S., Khan, O., Bergthold, G., Liu, B., Kalaitzidou, M., Huseni, M., Scheffold, C., Powles, T., & Choueiri, T. K.
Venue
The Lancet
Publisher
Elsevier BV
Published
2023-07
Volume
402
Issue
10397
Pages
185-195
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4379389239
Cited by
211
References
7
FWCI
33.52
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(23)00922-4
The paper
Pal, S. K., Albiges, L., Tomczak, P., Suárez, C., Voss, M. H., de Velasco, G., Chahoud, J., Mochalova, A., Procopio, G., Mahammedi, H., Zengerling, F., Kim, C., Osawa, T., Angel, M., Gupta, S., Khan, O., Bergthold, G., Liu, B., Kalaitzidou, M., . . . Choueiri, T. K. (2023). Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(23)00922-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.